Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement